ArticleInternational journal of nanomedicine2025
Bosentan Delivery via Nano Metal-Organic Framework nanoMIL-89 Restores Vascular Homeostasis in Pulmonary Arterial Hypertension.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- HBiomedicines · 2026Article
- Progress in mechanistic and clinical translational research of endothelin A receptor antagonists in the treatment of diabetic kidney disease: a narrative review.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary arterial hypertension (PAH) is a progressive vascular disorder characterized by endothelial dysfunction, smooth muscle proliferation, and inflammation. Current treatments, such as Bosentan (an endothelin receptor antagonist), are limited by systemic toxicity and a short half-life. This study aimed to evaluate a nanomedicine formulation of Bosentan using the iron-based metal-organic framework MIL-89 (nanoMIL-89) as a targeted drug delivery platform. Methods: Bosentan-loaded nanoMIL-89 (Bosentan@nanoMIL-89) was synthesized and characterized using microscopy, XRD, FTIR, and HPLC. In vitro assays were conducted on human umbilical vein endothelial cells (HUVECs) and human pulmonary artery smooth muscle cells (HPASMCs) under both basal and lipopolysaccharide (LPS)-induced inflammatory conditions. Results: Bosentan@nanoMIL-89 exhibited no significant cytotoxic or genotoxic effects while maintaining cellular viability. Under basal conditions, it reduced CXCL8 expression by up to 64.38% in HUVECs and 43.34% in HPASMCs. In lipopolysaccharide (LPS)-induced inflammatory conditions, CXCL8 suppression was further enhanced to 94.20% in HUVECs and 58.14% in HPASMCs. In HUVECs, Bosentan@nanoMIL-89 also decreased endothelin-1 (ET-1) release by up to 96.68% and reduced reactive oxygen species (ROS) levels by 46.17% under non-inflammatory conditions. These dose-dependent effects underscore its potent anti-inflammatory and antioxidant properties. Furthermore, Bosentan@nanoMIL-89 promoted angiogenic activity in HUVECs, suggesting therapeutic potential for vascular repair. Conclusion: These findings highlight Bosentan@nanoMIL-89 as a promising nanotherapeutic platform for PAH. By improving efficacy while mitigating systemic side effects, this approach reinforces the broader potential of MOF-based drug delivery systems in the management of vascular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.